|
PGBD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.55111512312578E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62747593179802E-12 |
| Normal-vs-Stage2 |
9.65830000000389E-05 |
| Normal-vs-Stage3 |
1.65256697215455E-12 |
| Normal-vs-Stage4 |
7.17649994985692E-09 |
| Stage1-vs-Stage2 |
2.463400E-01 |
| Stage1-vs-Stage3 |
3.188600E-01 |
| Stage1-vs-Stage4 |
2.617800E-01 |
| Stage2-vs-Stage3 |
8.353800E-02 |
| Stage2-vs-Stage4 |
8.940100E-02 |
| Stage3-vs-Stage4 |
6.058200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.589400E-04 |
| Normal-vs-Asian |
1.004710E-03 |
| Caucasian-vs-AfricanAmerican |
2.898400E-01 |
| Caucasian-vs-Asian |
8.264700E-03 |
| AfricanAmerican-vs-Asian |
4.577800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.00639554654481E-11 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
2.626200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63591362678517E-12 |
| Normal-vs-Age(41-60Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(61-80Yrs) |
1.60750002198284E-09 |
| Normal-vs-Age(81-100Yrs) |
1.802640E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.158000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.181800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.224200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.123200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.806810E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.294600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.80278999999395E-05 |
| Classical-VS-Follicular |
2.602800E-01 |
| Classical-VS-Other |
7.317400E-01 |
| Classical-VS-Normal |
5.76771963523015E-12 |
| Tall-VS-Follicular |
4.636500E-03 |
| Tall-VS-Other |
1.584980E-01 |
| Tall-VS-Normal |
1.62547753035369E-12 |
| Follicular-VS-Other |
4.595200E-01 |
| Follicular-VS-Normal |
1.33429933768525E-11 |
| Other-VS-Normal |
1.393180E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.92619311798626E-14 |
| Normal-vs-N1 |
1.18989999997599E-06 |
| N0-vs-N1 |
8.280400E-01 |
|
|
